Efficacy and safety of bevacizumab combined with EGFR‐TKIs in advanced non‐small cell lung cancer: A meta‐analysis
Autor: | Wenbo Liu, Yi Li, Xin Nie, Xu Li, Ping Zhang, Ailing Li, Bin Ai, Liming Wang, Yifan Yang, Shuai Zhang, Xiaonan Wu, Jiangyong Yu |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Lung Neoplasms Bevacizumab Cochrane Library bevacizumab NSCLC law.invention Antineoplastic Agents Immunological Randomized controlled trial law Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans cancer Lung cancer Adverse effect Protein Kinase Inhibitors EGFR‐TKI RC254-282 Randomized Controlled Trials as Topic business.industry Hazard ratio Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens General Medicine Original Articles medicine.disease Progression-Free Survival ErbB Receptors meta‐analysis Relative risk Drug Therapy Combination Original Article business medicine.drug |
Zdroj: | Thoracic Cancer, Vol 13, Iss 1, Pp 31-37 (2022) Thoracic Cancer |
ISSN: | 1759-7706 1759-7714 |
Popis: | Background The aim of this study was to estimate the efficacy and safety of bevacizumab combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in advanced non‐small cell lung cancer (NSCLC) patients. Methods We searched randomized controlled trials (RCTs) on bevacizumab combined with EGFR TKIs in the NSCLC Cochrane Library, Web of Science, PubMed and Embase. The data were extracted and assessed according to the Cochrane Handbook. We calculated the hazard ratio (HR), risk ratio (RR), and confidence interval (CI), and accomplished this meta‐analysis with Stata 14 software. Results Of 1301 articles scanned, five articles were involved in this meta‐analysis. We determined that compared with using EGFR TKIs alone, combination treatment significantly prolongs progression‐free survival (PFS) (HR = 0.61, 95% CI = 0.52–0.70; p |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |